「香港大學眼科學系與世界各地之 視網膜專家合作參與香港新抗血管 內皮生長因子治療的測試和研究。」 “HKU Ophthalmology works with an international network of retinal experts, conducting landmark clinical trials in the testing of new anti-VEGF treatments.” 5. Anti-vascular endothelial growth factor (VEGF) therapy – Innovating and testing new treatments for age-related macular degeneration With the introduction of anti- vascular endothelial growth factor (VEGF), millions of patients with age-related macular degeneration have been successfully treated worldwide. HKU Ophthalmology has been closely involved in the testing of new anti-VEGF treatments in multi-center clinical trials. By bringing in longer lasting and more e�ective drugs, we minimize the treatment burden of our patients. HKU Ophthalmology works with an international network of retinal experts, conducting landmark clinical trials in the testing of ranibizumab, aflibercept, conbercept, faricimab, brolucizumab and abicipar. We continue to impact patient care by o�ering new treatment options to our patients, ensuring safety of the new treatments with evidence-based protocols. 隨著抗血管內皮生長因子（VEGF）治療的引入， 全球數百萬老年黃斑部病變患者得到治愈。香港 大學眼科學系一直參與新抗血管內皮生長因子治 療的測試和研究。通過為患者帶來更持久、更有 效的藥物，讓患者的治療負擔降至最低。香港大 學眼科學系與世界各地之視網膜專家合作，進行 了具標誌性的雷珠單抗、阿柏西普、康柏西普、 法瑞昔單抗、布西珠單抗和阿比西帕的醫學測試 和臨床試驗。我們會繼續為患者提供新的治療方 案，以循證議定為基礎確保新治療的安全性。 抗血管內皮生長因子（VEGF）療法⸺ 創新測試方案以治療老年黃斑部病變 29 HKU Eye Center Inaugural Report The University of Hong Kong
RkJQdWJsaXNoZXIy Mzg4NDg0